Comparative Pharmacology
Head-to-head clinical analysis: DEPAKOTE CP versus LYRICA CR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPAKOTE CP versus LYRICA CR.
DEPAKOTE CP vs LYRICA CR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Valproate increases GABA concentration in the brain by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase. It also blocks voltage-gated sodium channels and T-type calcium channels.
Binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing calcium influx and inhibiting excitatory neurotransmitter release (e.g., glutamate, norepinephrine, substance P).
250-500 mg orally twice daily, titrated by 250 mg/day every 3-7 days; maximum 60 mg/kg/day. Target trough serum concentration: 50-100 mcg/mL.
Initial 75 mg orally twice daily (150 mg/day), or 50 mg three times daily (150 mg/day). Based on efficacy and tolerability, may increase to 150 mg twice daily (300 mg/day) after 1 week, then to 225 mg twice daily (450 mg/day) if needed. Maximum dose 450 mg/day. Take with food. Administer whole; do not split, crush, or chew.
None Documented
None Documented
Terminal elimination half-life is 9-16 hours (mean ~12 hours) in adults; prolonged in hepatic impairment, elderly, and neonates.
6.3 hours (mean terminal elimination half-life); correlates with creatinine clearance, prolonged in renal impairment.
Renal: 30-50% as glucuronide conjugates, 3% as unchanged drug; fecal: minimal; less than 3% excreted in bile.
Primarily renal excretion as unchanged drug (98-99% of absorbed dose); <0.1% biliary/fecal.
Category C
Category C
Anticonvulsant
Anticonvulsant